NCT01239771View on ClinicalTrials.gov

A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
Interventions
DRUG

TC-5214

Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.

DRUG

Placebo

Two subjects in each cohort will be given placebo.

Trial Locations (1)

Unknown

Research Site, Uppsala

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY